InvestorsObserver is giving Recursion Pharmaceuticals Inc (RXRX) an Analyst Rating Rank of 17, meaning RXRX is ranked higher by analysts than 17% of stocks. The average price target for RXRX is $16 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating RXRX a Buy today. Find out what this means to you and get the rest of the rankings on RXRX!
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Recursion Pharmaceuticals Inc Stock Today?
Recursion Pharmaceuticals Inc (RXRX) stock is trading at $10.63 as of 12:45 PM on Thursday, Aug 18, a drop of -$0.89, or -7.73% from the previous closing price of $11.52. The stock has traded between $10.47 and $11.32 so far today. Volume today is low. So far 485,012 shares have traded compared to average volume of 958,691 shares.
Click Here to get the full Stock Report for Recursion Pharmaceuticals Inc stock.